From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades

Developing biomarkers for accurately predicting the efficacy of immune checkpoint inhibitor (ICI) therapies is conducive to avoiding unwanted side effects and economic burden. At the moment, the quantification of programmed cell death ligand 1 (PD-L1) in tumor tissues is clinically used as one of th...

Full description

Bibliographic Details
Main Authors:	Xuan Zhao, Yulin Bao, Bi Meng, Zijian Xu, Sijin Li, Xu Wang, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Immunology
Subjects:	PD-L1 immune checkpoint inhibitors tumor immunotherapy biomarker liquid biopsy tumor microenvironment
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.920021/full

Similar Items

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
by: Fabian Krutzek, et al.
Published: (2022-06-01)

PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed
by: Weijia Huang, et al.
Published: (2022-10-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
by: Ana Bocanegra, et al.
Published: (2020-08-01)

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
by: Fang Yang, et al.
Published: (2021-12-01)

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
by: Xianjie Jiang, et al.
Published: (2019-01-01)

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
by: Yunzhou Pu, et al.
Published: (2022-05-01)

Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer
by: Kevin Chih-Yang Huang, et al.
Published: (2020-02-01)

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma
by: Zhang-Wei Hu, et al.
Published: (2022-08-01)

Prospect of Tumor Treatment in the Post-PD-1/PD-L1 Inhibitor Era
by: SHAN Baoen
Published: (2023-09-01)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
by: Laure Chardin, et al.
Published: (2021-12-01)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
by: Tian Tian, et al.
Published: (2021-09-01)

Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
by: Mohamed Eltahir, et al.
Published: (2021-06-01)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
by: Junyu Long, et al.
Published: (2017-08-01)

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
by: Shengzhe Jin, et al.
Published: (2024-03-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
by: Keyu Yuan, et al.
Published: (2022-09-01)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
by: Faisal K. Alkholifi, et al.
Published: (2022-11-01)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
by: Junjie Liu, et al.
Published: (2022-09-01)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
by: Zhitao Li, et al.
Published: (2021-11-01)

Spatial Profile of Tumor Microenvironment in PD-L1-Negative and PD-L1-Positive Triple-Negative Breast Cancer
by: Liubov A. Tashireva, et al.
Published: (2023-01-01)

Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment
by: James L. Gulley, et al.
Published: (2022-06-01)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
by: Rui Zhao, et al.
Published: (2021-01-01)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
by: Yu Yuan, et al.
Published: (2021-02-01)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
by: Meng Chen, et al.
Published: (2022-11-01)

Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs
by: Simin Ahmadvand, et al.
Published: (2024-01-01)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
by: Zijun Y. Xu-Monette, et al.
Published: (2017-12-01)

Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials
by: C. Bryce Johnson, et al.
Published: (2018-04-01)

Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade
by: Haoran Zha, et al.
Published: (2017-10-01)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
by: Huiyu Yan, et al.
Published: (2023-10-01)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
by: Ming Yi, et al.
Published: (2022-12-01)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
by: Yuedi Zhang, et al.
Published: (2022-06-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
by: Yiru Zhang, et al.
Published: (2023-01-01)

PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages
by: Zhiyuan Zhu, et al.
Published: (2020-11-01)

AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses
by: Bi Meng, et al.
Published: (2023-09-01)

Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment
by: Jun Zheng, et al.
Published: (2023-02-01)

PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread
by: Tiina Vesterinen, et al.
Published: (2019-08-01)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
by: Bogang Wu, et al.
Published: (2018-11-01)